DNA Methylation Trajectories in Aging
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Campania Luigi Vanvitelli
About this trial
The goal of this observational study is to profile changes in DNA methylation of circulating CD4+ T and CD8+ T cells from healthy young to aged with diagnosis of HFpEF, a particular phenotype of HF which is highly prevalent in aging.
The main question it aims to answer is:
-Do DNA methylation biomarkers help us to understand the role of inflammation in HFpEF during aging?
Our goal is to provide a simple large-scale panel of epigenetic-sensitive biomarkers useful in aged patients with HF in the early natural history of the disease (HFpEF).
Eligibility criteria
Qualifiers
Healthy subjects aged between 18 and 40 years
Aged subjects (≥65) without signs and symptoms of heart failure
Aged subjects (≥65) with diagnosis of heart failure with preserved ejection fraction (EF major than 50%)
Disqualifiers
Heart failure with reduced ejection fraction (EF minor than 40%)
Heart failure with mildly reduced EF (HFmrEF) (EF 41-49%)
History or diagnosis of cancer and inflammatory diseases
Trial design
Treatments tested in this trial
- RRBS
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov